Skip to content
TheChatArchiveThe Chat Archive
gpt-4o-2024-08-06· OpenAIAi2 WildChat-4.8M (AI2)

You act as a paraphrase tool. Your role involves understanding the provided text…

  1. User

    System: You act as a paraphrase tool. Your role involves understanding the provided text and then providing a positive example that keeps the original meaning of the text unchanged while using synonyms, interchanging, adding or removing words or sentences, and then provide a negative example where the meaning of the original text is at its opposite. Output your response with the following format : Positive : Negative :

    User: In order to secure the necessary regulatory clearances for the acquisition of Bayer Animal Health, we signed agreements to divest the rights to manufacture and commercialize certain products. The following table summarizes the financial impact of the material divestitures completed during 2020 in connection with the acquisition of Bayer Animal Health, of which the pre-tax gains and losses are included in other expense (income), net in the consolidated and combined statement of operations. | For the Year Ended December 31, 2020 | | Gross Cash Proceeds | | Pre-tax Gain | Osurnia | ∣140.5∣∣∣| 140.5 | | | | 93.2 | | Vecoxan | 55.1 | | | 37.2 | | Capstar | 95.9 | | | 25.6 | | Drontal and Profender | 140.6 | | | — | | Other immaterial divestitures | 2.6 | | | 0.7 | | Total (1) | ∣434.7∣∣∣| 434.7 | | | | 156.7 | | (1)Pre-tax gain is net of transaction costs of $13.3 million. We determined that the disposal of the related net assets does not qualify for reporting as a discontinued operation because it does not represent a strategic shift that has or will have a major effect on our operations and financial results. Assistant:

  2. Assistant

    Positive: To obtain the essential regulatory approvals for purchasing Bayer Animal Health, we entered into agreements to sell off our rights to produce and market certain products. The table below details the financial consequences of significant divestitures finalized in 2020 as part of acquiring Bayer Animal Health, with pre-tax gains and losses included in other expenses (income), net, in the consolidated and combined statement of operations. | For the Year Ended December 31, 2020 | | Gross Cash Receipts | | Pre-tax Profit | Osurnia | ∣140.5∣∣∣| 140.5 | | | | 93.2 | | Vecoxan | 55.1 | | | 37.2 | | Capstar | 95.9 | | | 25.6 | | Drontal and Profender | 140.6 | | | — | | Other insignificant divestitures | 2.6 | | | 0.7 | | Total (1) | ∣434.7∣∣∣| 434.7 | | | | 156.7 | | (1) Pre-tax profit is after accounting for transaction fees of $13.3 million. The disposal of the linked net assets doesn't qualify as a discontinued operation since it doesn’t lead to a strategic shift with a major impact on our operations and financial results.

    Negative: To prevent gaining the necessary regulatory approvals for acquiring Bayer Animal Health, we refused to sign agreements that would involve divesting the rights to manufacture and market certain products. The subsequent table undermines the financial impact of material divestitures avoided during 2020 concerning the acquisition of Bayer Animal Health, where the pre-tax gains and losses are excluded from other expense (income), net in the consolidated and combined statement of operations.